Topic:

R&D

Latest Headlines

Latest Headlines

Augmedix grabs $3.2M for Google Glass-enabled medical records physician tool

With Augmedix's new $3.2 million in venture funding, the use of Google Glass for healthcare gets a major boost. The San Francisco startup uses Google Glass technology to help doctors more efficiently push information to most electronic health records systems and also verbally seek information from them, according to the company's website.

C.R. Bard enrolls first patient in a new U.S. clinical trial of its drug-coated balloon

C.R. Bard enrolled its first patient in a new U.S. clinical trial of its drug-coated balloon. The technology could provide an alternative to traditional treatment methods for in-stent restenosis, the company said in a statement.

New incontinence data could give Ipsen's Dysport a path to lucrative urology use

Ipsen announced "positive results" in a Phase II trial of Dysport in patients with urinary incontinence. That could put Ipsen's drug in line for more head-to-head competition with Allergan's Botox, which has successfully expanded into several medical uses.

Meet RestorGenex, a biotech mosaic from Celgene founder Barer

Nearly three years removed from his Celgene retirement, Sol Barer is working to get another biotech off the ground, piecing together four drugmakers into a whole called RestorGenex and setting out to make a difference in dermatology, ocular diseases and women's health.

AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project

MD Anderson's popular "moon-shot" immuno-oncology research project has won over another big industry player looking to play catch-up in the hottest race in cancer drug R&D. AstraZeneca's biologics arm, MedImmune, has become the latest Big Pharma player to join a team that has already attracted Pfizer and J&J.

Eager biotechs eye $133M in IPOs as a frenzied quarter closes

Three more drug developers are angling to go public in the waning days of a bustling first quarter for biotech IPOs, swinging for a combined $133 million to bankroll their programs. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune have all queued up for Wall Street debuts, hoping 2014's bull market lasts long enough to pull off offerings.

Upbeat review of PhII DMD trial earns Prosensa a big boost to shares

After the markets closed last night, Prosensa issued an upbeat self-assessment of its 48-week extension data from a Phase II study of its lead drug drisapersen for Duchenne muscular dystrophy.

Intercept's lead drug boasts success in PhIII after worrisome side-effects disclosure

Intercept Pharmaceuticals delivered a bad news-good news punch over the weekend about its lead drug.

Amgen goes 6-for-6 in Phase III, leading the race for a new cardio blockbuster

Amgen's promising cardio drug aced its 6th late-stage study, the company said, beating out statins in patients with a cholesterol-boosting genetic disorder and widening the drugmaker's lead in a potentially lucrative new field.

PPD lands a federal bioterror deal worth up to $100M

PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.